Aligos Therapeutics Banks $25M Upfront in Greater China Hepatitis B Deal
Aligos Therapeutics received a $25 million upfront payment and could earn up to $420 million in milestones from an exclusive Greater China license for its hepatitis B candidate.
Non-dilutive capital is oxygen for a clinical-stage biotech, and Aligos Therapeutics just took a deep breath. On July 6, 2026, the South San Francisco company said it had received a $25 million upfront payment from Xiamen Amoytop Biotech under an exclusive license covering pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.
Aligos is a clinical-stage developer focused on liver and viral diseases. Chronic hepatitis B remains a large, underserved market, and the deal validates one of the company's lead assets while keeping Aligos in control of major territories including the United States, Europe, Japan and South Korea.
The upside case rests on the deal's structure. Beyond the $25 million upfront, Aligos is eligible for up to $420 million in clinical, regulatory and sales milestones, plus tiered high single-digit royalties. Pevifoscorvir sodium has already secured Breakthrough Therapy Designation from China's Center for Drug Evaluation, opening a path to priority review there.
Milestone payments are contingent on clinical and regulatory success that is far from guaranteed. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.
Get the next one first.
Small-cap biotech catalysts, filings and movers — free.
